In this study, we develop a nanoinhibitor, BIP-MPC-NP, which can simultaneously mitigate the crosstalk between EGFR and MET signaling pathways contributing to the TMZ resistance by conjugating Inherbin3 and cMBP on the surface of NHS-PEG8-Mal modified MPC-nanoparticle in glioma. This evidence concerns the gene EGFR and central nervous system cancer.